Division of Cancer Research and Training, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA.
David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Biomolecules. 2024 Jan 14;14(1):105. doi: 10.3390/biom14010105.
The low bioavailability of most phytochemicals limits their anticancer effects in humans. The present study was designed to test whether combining arctigenin (Arc), a lignan mainly from the seed of , with green tea (GT) and quercetin (Q) enhances the chemopreventive effect on prostate cancer. We performed in vitro proliferation studies on different cell lines. We observed a strong synergistic anti-proliferative effect of GT+Q+Arc in exposing androgen-sensitive human prostate cancer LNCaP cells. The pre-malignant WPE1-NA22 cell line was more sensitive to this combination. No cytotoxicity was observed in normal prostate epithelial PrEC cells. For an in vivo study, 3-week-old, prostate-specific PTEN (phosphatase and tensin homolog) knockout mice were treated with GT+Q, Arc, GT+Q+Arc, or the control daily until 16 weeks of age. In vivo imaging using prostate-specific membrane antigen (PSMA) probes demonstrated that the prostate tumorigenesis was significantly inhibited by 40% (GT+Q), 60% (Arc at 30 mg/kg bw), and 90% (GT+Q+Arc) compared to the control. A pathological examination showed that all control mice developed invasive prostate adenocarcinoma. In contrast, the primary lesion in the GT+Q and Arc alone groups was high-grade prostatic intraepithelial neoplasia (PIN), with low-grade PIN in the GT+Q+Arc group. The combined effect of GT+Q+Arc was associated with an increased inhibition of the androgen receptor, the PI3K/Akt pathway, Ki67 expression, and angiogenesis. This study demonstrates that combining Arc with GT and Q was highly effective in prostate cancer chemoprevention. These results warrant clinical trials to confirm the efficacy of this combination in humans.
大多数植物化学物质的生物利用度低,限制了它们在人类中的抗癌作用。本研究旨在测试是否将来自 的种子中的木脂素(Arctigenin,Arc)与绿茶(GT)和槲皮素(Q)联合使用可以增强对前列腺癌的化学预防作用。我们在不同的细胞系上进行了体外增殖研究。我们观察到 GT+Q+Arc 对雄激素敏感的人前列腺癌细胞 LNCaP 具有强烈的协同抗增殖作用。前恶性 WPE1-NA22 细胞系对这种组合更为敏感。在正常前列腺上皮细胞 PrEC 中未观察到细胞毒性。对于体内研究,我们用 GT+Q、Arc、GT+Q+Arc 或对照物每天处理 3 周龄的前列腺特异性 PTEN(磷酸酶和张力蛋白同源物)敲除小鼠,直到 16 周龄。使用前列腺特异性膜抗原(PSMA)探针进行体内成像表明,与对照相比,前列腺肿瘤发生分别被 GT+Q(40%)、Arc(30mg/kg bw,60%)和 GT+Q+Arc(90%)显著抑制。病理检查显示,所有对照小鼠均发生侵袭性前列腺腺癌。相比之下,GT+Q 和 Arc 单独组的原发性病变为高级别前列腺上皮内瘤变(PIN),GT+Q+Arc 组为低级别 PIN。GT+Q+Arc 的联合作用与雄激素受体、PI3K/Akt 通路、Ki67 表达和血管生成的抑制增加有关。本研究表明,将 Arc 与 GT 和 Q 联合使用对前列腺癌的化学预防非常有效。这些结果需要临床试验来确认该组合在人类中的疗效。